| Literature DB >> 30993011 |
Tim Kraal1, Lijkele Beimers2, Bertram The3, Inger Sierevelt2, Michel van den Bekerom3, Denise Eygendaal1.
Abstract
Manipulation under anaesthesia (MUA) for frozen shoulder (FS) leads to a considerable increase in range of motion and Oxford shoulder score, a significant reduction in pain and around 85% satisfaction.A clearly defined indication for MUA in FS patients cannot be extracted from this review or the available literature. The associating criteria before proceeding to MUA vary widely.All but one study in this review lacked a control group without intervention. Therefore, firm conclusions about the role of MUA in the treatment of FS cannot be drawn from the current literature.An overall complication rate of 0.4% was found and a re-intervention rate of 14%, although most of the included papers were not designed to monitor complications.The following criteria before proceeding to MUA are proposed: a patient unable to cope with a stiff and painful shoulder; clinical signs of a stage 2 idiopathic FS; lessening pain in relation to stage 1; external rotation < 50% compared to contralateral shoulder joint; a minimal duration of symptoms of three months; and failure to respond to an intra-articular corticosteroid infiltration. Cite this article: EFORT Open Rev 2019;4:98-109. DOI: 10.1302/2058-5241.4.180044.Entities:
Keywords: adhesive capsulitis; frozen shoulder; manipulation
Year: 2019 PMID: 30993011 PMCID: PMC6440298 DOI: 10.1302/2058-5241.4.180044
Source DB: PubMed Journal: EFORT Open Rev ISSN: 2058-5241
Codman’s criteria for frozen shoulder
| Symptoms | Condition comes on slowly |
|---|---|
| Pain is felt near the insertion of deltoid | |
| Inability to sleep on the affected side | |
| Able to continue daily habits and routines | |
| Signs | Painful, restricted elevation |
| Painful restricted external rotation | |
| Restriction of both the active and passive type | |
| Atrophy of the spinate | |
| Little local tenderness | |
| Investigations | Normal results on radiography |
Related conditions associated with secondary frozen shoulder
| Condition | Example |
|---|---|
| Systemic conditions | Diabetes mellitus, thyroid disorders, hypo-adrenalism |
| Trauma | Proximal humeral fracture, clavicle fracture |
| Post-operative | Immobilization of the upper limb |
| Breast cancer treatment | Surgery or radiation therapy on the chest wall and axilla |
| Neurological conditions | Cervical radiculopathy, stroke |
Figure 1.Flow diagram showing the result and evaluation process of our search, according to the PRISMA algorithm.
Characteristics of studies included in this review
| Study design | Type of PS (as stated by authors) | Patients (n) | Age (mean, years) | Time onset to MUA (months) | Diabetes | Corticosteroids | Mean follow-up (months) | MINOR score |
|---|---|---|---|---|---|---|---|---|
| Prospective cohort | Primary, ‘frozen’ | 39 | 53 | 8 (3-15) | Excluded | Yes | 11 (6-18) | 8 |
| Retrospective cohort | Idiopathic | 19 | 50 | 11 (2-36) | n = 8 (results not separately reported) | No | 180 (97-247.2) | 9 |
| Retrospective cohort | Idiopathic | 145 | 60 | 6.5 | Excluded | Yes | 62 (12-125) | 9 |
| Prospective randomized trial | Primary, ‘freezing’ | 25 | 57 | 4.2 | Excluded | No | Mean not reported, goal 24 | 13 |
| Retrospective case control | Primary and secondary | 214 | 51 | 6 | n = 39 | Yes | 43 (8-127) | 10 |
| Prospective randomized trial | Not clearly stated | 65 | 53 | 7.4 (3-22) | n = 9 (results not separately reported) | No | Mean not reported, goal 12 | 13 |
| Prospective (non-randomized) comparative | Idiopathic, ‘frozen’ | 30 | 52 | 9.9 | Excluded | Yes, subacromial in 50% | Mean not reported, goal 12 | 12 |
| Retrospective cohort | Not clearly stated, post-traumatic excluded | 74 | 53 | 7.2 (1-20) | n = 5 (results not separately reported) | Yes | 33 | 7 |
| Prospective cohort | Idiopathic | 39 | 50 | 7.3 (4-12) | Excluded | No | 40.8 (26.4-51.6) | 9 |
| Prospective cohort | Not clearly stated | 32 | 49 | 7.3 | n = 4 (results not separately reported) | Yes, orally | 14.4 | 8 |
| Prospective randomized trial | Primary, stage II | 16 | 55 | 8.8 (4-23) | n = 3 (re-intervention) | Yes | 2.6 | 11 |
| Prospective cohort | Idiopathic | 15 | 54 | 8.6 (3-12) | Not reported | Yes | Mean not reported, goal 6 | 9 |
| Retrospective cohort | Idiopathic ‘spontaneous’ | 22 | 53 | Not reported | n = 5 | No | 168 (24-288) | 8 |
| Retrospective cohort | Idiopathic ‘spontaneous’ | 16 | 49 | 7.6 (4-12) | n = 4 | No | 276 (228-360) | 7 |
| Retrospective cohort | Idiopathic ‘spontaneous’ | 65 | 54 | Not reported | n = 10 (results not separately reported) | No | 72 | 9 |
| Retrospective, non-randomized, comparative | Idiopathic | 42 | 56 | 7.4 (3-18) | n = 21 | Yes | 95 (18-189) | 7 |
Various diagnostic criteria, cut-off values and imaging used in the diagnosis of frozen shoulder. The sequence of manipulation and the preventative measures as described in the included studies
| Investigator | Year | Diagnostic criteria | Minimal duration of symptoms | Imaging | Sequence of manipulation | Additional preventative measures |
|---|---|---|---|---|---|---|
| Dodenhoff et al | 2000 | Lessening pain compared to stage I | n.a. | CR | ABD, EXT in ABD, EXT at side, ADD, INT | Scapular stabilization, short lever arm |
| Farrel et al | 2005 | Pain and limited active and passive ROM | n.a. | CR + MRI or arthrography | FLEX, EXT in ABD, ABD, INT, ADD | Gentle pressure on distal humerus |
| Flannery et al | 2007 | Codman’s criteria | 3 months | n.a. | FLEX, EXT, ADD, INT | Scapular stabilization, grip on inner aspect proximal humerus |
| Jacobs et al | 2009 | n.a. | n.a. | CR | ADD, FLEX, EXT, INT, ABD | Scapular stabilization, short lever arm |
| Jenkins et al | 2012 | n.a. | n.a. | n.a. | ABD, FLEX, EXT, ADD, INT | n.a. |
| Kivimäki et al | 2007 | Gradually increasing pain and stiffness, FLEX < 140, EXT < 30 | n.a. | n.a. | FLEX, ABD, INT in 90, EXT in 90 | Scapular stabilization |
| Meyer et al | 2015 | Codman’s criteria, ABD < 90 | 6 months | CR + MRI | ABD, EXT in ABD, EXT in ADD, INT | Scapular stabilization |
| Othman et al | 2002 | FLEX < 100, EXT < 50% compared to contralateral side | 1 month | CR | Alternate FLEX, ABD, EXT | Scapular stabilization, grip high on the proximal humerus |
| Pap et al | 1998 | Lessening pain | 4 months | CR + ultrasound | ABD, ADD, FLEX, EXT, INT | n.a. |
| Placzek et al | 1998 | Pain at end ROM, total ROM loss > 40% | 2 months | n.a. | ABD and FLEX, INT and EXT | Translational gliding technique, scapular stabilization |
| Quraishi et al | 2007 | Global loss of active and passive ROM, EXT < 50% | n.a. | CR | n.a. | Short lever arm |
| Sokk et al | 2012 | ROM < 50% compared to contralateral side in 1 of 3 directions, inability to sleep on affected side | n.a. | CR | FLEX, EXT at side, EXT in 90, INT, ADD | Scapular stabilization, using thumb and opposing 2 fingers |
| Vastamaki et al | 2012 | FLEX < 135, ABD < 125, ‘severe’ restriction in EXT, pain at end ROM | 5 to 6 months | CR | n.a. | n.a. |
| Vastamaki et al | 2013 | FLEX + ABD < 120, EXT + INT ‘almost absent’ | 6 months | CR | Gradual alternate ABD, FLEX, EXT, INT | ‘Care not to fracture the humerus’ |
| Vastamaki et al | 2015 | FLEX < 120, ABD < 110, ‘severe’ restriction in EXT | n.a. | CR | Gradual alternate ABD, FLEX, EXT, INT | ‘Care not to fracture the humerus’ |
| Wang et al | 2010 | FLEX < 100, EXT < 50% compared to contralateral side | 1 month | CR + ultrasound | FLEX, EXT at side, EXT in 90, INT, ADD | Scapular stabilization, forced carefully applied with two thumbs |
n.a., not available; CR, conventional radiography; ABD, abduction; EXT, external rotation; ADD, adduction; INT, internal rotation
Results of the pooled analysis in shoulder joint range of motion (ROM), per follow-up period after manipulation. Results are shown as weighted mean differences (WMD) from baseline with 95% confidence intervals (CI) for flexion, abduction and external rotation. Study heterogeneity is shown as I2
| Weighted mean difference from baseline (WMD) | 95% CI | p-value | f value % | ||
|---|---|---|---|---|---|
| Baseline mean ROM in degrees (SD) | 80.4 (29.4) | ||||
| 1-6 weeks | 55.2 | 32.7- to 78.0 | < 0.0001 | 98 | |
| 6-12 weeks | 45.0 | 34.3 to 55.7 | < 0.0001 | 53 | |
| 3-6 months | 66.4 | 45.3 to 87.6 | < 0.0001 | 92 | |
| 6-12 months | 69.4 | 37.8 to 101.1 | < 0.0001 | 96 | |
| > 12 months | 67.3 | 54.6 to 80.1 | < 0.0001 | 89 | |
| Baseline mean ROM in degrees (SD) | 65.8 (24.7) | ||||
| 1-6 weeks | 72.5 | 48.5 to 96.4 | < 0.0001 | 97 | |
| 6-12 weeks | 70.5 | 62.6 to 78.4 | < 0.0001 | 0 | |
| 3-6 months | 86.6 | 29.2 to 116.1 | < 0.0001 | 95 | |
| 6-12 months | 95.4 | 71.9 to 118.9 | < 0.0001 | 94 | |
| > 12 months | 91.8 | 84.3 to 99.3 | 0.03 | 62 | |
| Baseline mean ROM in degrees (SD) | 22.2 (14.2) | ||||
| 1-6 weeks | 30.5 | 17.4 to 43.6 | < 0.0001 | 96 | |
| 6-12 weeks | 21.2 | 9.2 to 33.2 | 0.008 | 79 | |
| 3-6 months | 29.4 | 12.0 to 46.7 | < 0.0001 | 93 | |
| 6-12 months | 44.8 | 38.9 to 50.6 | 0.23 | 32 | |
| > 12 months | 42.0 | 32.8 to 51.3 | < 0.0001 | 83 |
Results of the pooled analysis of pain (visual analogue scale (VAS)), Constant score (CMS) and adjusted Constant score, per follow-up period after manipulation. Reduction in pain and improvement in Constant score are shown as weighted mean difference (WMD) from baseline with 95% confidence intervals (CI). Study heterogeneity is shown as I2
| Weighted mean difference from baseline (WMD) | 95% CI | p-value | f value % | ||
|---|---|---|---|---|---|
| Baseline mean VAS (SD) | 6.9 (1.4) | ||||
| 1-6 weeks | -3.5 | -7.0 to -0.1 | < 0.0001 | 99 | |
| 6-12 weeks | -2.0 | -3.6 to -0.4 | 0.02 | 82 | |
| 3-6 months | -4.0 | -5.5 to -2.4 | 0.03 | 78 | |
| 6-12 months | -5.1 | -5.2 to -5.0 | < 0.0001 | n.a. | |
| > 12 months | -5.1 | -6.9 to -3.3 | 0.002 | 93 | |
| Baseline mean CMS (SD) | 32.9 (8.8) | ||||
| 1-6 weeks | 43.5 | 31.8 to 55.2 | 0.001 | 90 | |
| 6 weeks to 6 months | 41.8 | 22.6 to 61.1 | < 0.0001 | 96 | |
| 6-12 months | 52.1 | 33.0 to 71.3 | < 0.0001 | 97 | |
| > 12 months | 41.6 | 38.0 to 45.3 | n.a. | n.a. | |
| Baseline mean Adjusted CMS (SD) | 24.8 (5.7) | ||||
| 1-6 weeks | 30.2 | 27.5 to 32.9 | < 0.0001 | n.a. | |
| > 12 months | 48.6 | 46.8 to 50.3 | 0.19 | 43 |